Peringatan Keamanan

Patients experiencing an acute overdose should be treated with symptomatic and supportive treatment.L11994 Chronic overdoses where patients require continued therapy can be treated through temporary dose reduction or alternate day treatment.L11994

The oral, intraperitoneal, and intravenous LD50 values in rats are 1877 mg/kg, 1179 mg/kg, and 1276 mg/kg, respectively.L14309

Betamethasone phosphate

DB14669

small molecule approved vet_approved

Deskripsi

Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible betamethasone to agonize glucocorticoid receptors.L11994 Betamethasone provides greater anti-inflammatory activity than prednisolone with less sodium and water retention.L11994

Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.L11994

Struktur Molekul 2D

Berat 472.446
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 12.47 ± 1.91 h.[A214277]
Volume Distribusi The volume of distribution of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 226.00 ± 61.64 L.[A214277]
Klirens (Clearance) The clearance of betamethasone in an intramuscular injection of 3mg betamethasone acetate and 3mg betamethasone phosphate is 12.62 ± 3.45 L/h.[A214277]

Absorpsi

An intramuscular injection of 3mg betamethasone acetate and 3mg betametasone phosphate reaches a betamethasone Cmax 33.21 ± 8.71 ng/mL, with a Tmax of 1.56 ± 1.32 h, and an AUC of 506.95 ± 125.03 ng\*h/mL.A214277

Metabolisme

Betamethasone phosphate is rapidly de-esterified to betamethasone.L11994

Rute Eliminasi

Corticosteroids are eliminated predominantly in the urine.A187436

Interaksi Obat

872 Data
Ceritinib The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Ceritinib.
Aldesleukin The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Betamethasone phosphate.
Corticorelin ovine triflutate The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Betamethasone phosphate.
Deferasirox The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when Betamethasone phosphate is combined with Deferasirox.
Hyaluronidase (ovine) The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Betamethasone phosphate.
Hyaluronidase (human recombinant) The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Betamethasone phosphate.
Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone phosphate.
Amphotericin B The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Amphotericin B.
Isoetharine The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Isoetharine.
Norepinephrine The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Norepinephrine.
Phenylpropanolamine The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Phenylpropanolamine.
Epinephrine The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Epinephrine.
Orciprenaline The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Orciprenaline.
Dobutamine The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Dobutamine.
Ritodrine The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Ritodrine.
Bitolterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Bitolterol.
Salmeterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Salmeterol.
Formoterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Formoterol.
Albuterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Salbutamol.
Isoprenaline The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Betamethasone phosphate.
Arbutamine The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Arbutamine.
Arformoterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Arformoterol.
Fenoterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Fenoterol.
Pirbuterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Pirbuterol.
Ephedra sinica root The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Ephedra sinica root.
Procaterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Procaterol.
Clenbuterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Clenbuterol.
Celiprolol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Celiprolol.
Indacaterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Indacaterol.
Droxidopa The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Droxidopa.
Protokylol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Protokylol.
Hexoprenaline The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Hexoprenaline.
Olodaterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Olodaterol.
Vilanterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Vilanterol.
Doxofylline The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Doxofylline.
Racepinephrine The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Racepinephrine.
Etafedrine The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Etafedrine.
PF-00610355 The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with PF-00610355.
Abediterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Abediterol.
Batefenterol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Batefenterol.
Levosalbutamol The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Levosalbutamol.
Mifepristone The therapeutic efficacy of Betamethasone phosphate can be decreased when used in combination with Mifepristone.
Mitotane The serum concentration of Betamethasone phosphate can be decreased when it is combined with Mitotane.
Dicoumarol Betamethasone phosphate may increase the anticoagulant activities of Dicoumarol.
Phenindione Betamethasone phosphate may increase the anticoagulant activities of Phenindione.
Warfarin Betamethasone phosphate may increase the anticoagulant activities of Warfarin.
Phenprocoumon Betamethasone phosphate may increase the anticoagulant activities of Phenprocoumon.
Acenocoumarol Betamethasone phosphate may increase the anticoagulant activities of Acenocoumarol.
4-hydroxycoumarin Betamethasone phosphate may increase the anticoagulant activities of 4-hydroxycoumarin.
Coumarin Betamethasone phosphate may increase the anticoagulant activities of Coumarin.
(R)-warfarin Betamethasone phosphate may increase the anticoagulant activities of (R)-warfarin.
Ethyl biscoumacetate Betamethasone phosphate may increase the anticoagulant activities of Ethyl biscoumacetate.
Fluindione Betamethasone phosphate may increase the anticoagulant activities of Fluindione.
Clorindione Betamethasone phosphate may increase the anticoagulant activities of Clorindione.
Diphenadione Betamethasone phosphate may increase the anticoagulant activities of Diphenadione.
Tioclomarol Betamethasone phosphate may increase the anticoagulant activities of Tioclomarol.
(S)-Warfarin Betamethasone phosphate may increase the anticoagulant activities of (S)-Warfarin.
Nicorandil The risk or severity of ulceration can be increased when Betamethasone phosphate is combined with Nicorandil.
Calcifediol The therapeutic efficacy of Calcifediol can be decreased when used in combination with Betamethasone phosphate.
Ergocalciferol The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Betamethasone phosphate.
Dihydrotachysterol The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Betamethasone phosphate.
Alfacalcidol The therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Betamethasone phosphate.
Seocalcitol The therapeutic efficacy of Seocalcitol can be decreased when used in combination with Betamethasone phosphate.
Inecalcitol The therapeutic efficacy of Inecalcitol can be decreased when used in combination with Betamethasone phosphate.
Becocalcidiol The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Betamethasone phosphate.
Eldecalcitol The therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Betamethasone phosphate.
1alpha,24S-Dihydroxyvitamin D2 The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Betamethasone phosphate.
Elocalcitol The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Betamethasone phosphate.
Maxacalcitol The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Betamethasone phosphate.
Doxercalciferol The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Betamethasone phosphate.
1alpha-Hydroxyvitamin D5 The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Betamethasone phosphate.
Vitamin D The therapeutic efficacy of Vitamin D can be decreased when used in combination with Betamethasone phosphate.
Calcitriol The therapeutic efficacy of Calcitriol can be decreased when used in combination with Betamethasone phosphate.
Cholecalciferol The therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Betamethasone phosphate.
Paricalcitol The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Betamethasone phosphate.
Previtamin D(3) The therapeutic efficacy of Previtamin D(3) can be decreased when used in combination with Betamethasone phosphate.
Diethylstilbestrol The serum concentration of Betamethasone phosphate can be increased when it is combined with Diethylstilbestrol.
Etonogestrel The serum concentration of Betamethasone phosphate can be increased when it is combined with Etonogestrel.
Desogestrel The serum concentration of Betamethasone phosphate can be increased when it is combined with Desogestrel.
Megestrol acetate The serum concentration of Betamethasone phosphate can be increased when it is combined with Megestrol acetate.
Levonorgestrel The serum concentration of Betamethasone phosphate can be increased when it is combined with Levonorgestrel.
Progesterone The serum concentration of Betamethasone phosphate can be increased when it is combined with Progesterone.
Medroxyprogesterone acetate The serum concentration of Betamethasone phosphate can be increased when it is combined with Medroxyprogesterone acetate.
Norethisterone The serum concentration of Betamethasone phosphate can be increased when it is combined with Norethisterone.
Estradiol The serum concentration of Betamethasone phosphate can be increased when it is combined with Estradiol.
Ethynodiol diacetate The serum concentration of Betamethasone phosphate can be increased when it is combined with Ethynodiol diacetate.
Norgestimate The serum concentration of Betamethasone phosphate can be increased when it is combined with Norgestimate.
Ethinylestradiol The serum concentration of Betamethasone phosphate can be increased when it is combined with Ethinylestradiol.
Mestranol The serum concentration of Betamethasone phosphate can be increased when it is combined with Mestranol.
Drospirenone The serum concentration of Betamethasone phosphate can be increased when it is combined with Drospirenone.
Estrone sulfate The serum concentration of Betamethasone phosphate can be increased when it is combined with Estrone sulfate.
Octylphenoxy polyethoxyethanol The serum concentration of Betamethasone phosphate can be increased when it is combined with Octylphenoxy polyethoxyethanol.
Cyproterone acetate The serum concentration of Betamethasone phosphate can be increased when it is combined with Cyproterone acetate.
Norelgestromin The serum concentration of Betamethasone phosphate can be increased when it is combined with Norelgestromin.
Gestodene The serum concentration of Betamethasone phosphate can be increased when it is combined with Gestodene.
Hydroxyprogesterone caproate The serum concentration of Betamethasone phosphate can be increased when it is combined with Hydroxyprogesterone caproate.
Norethynodrel The serum concentration of Betamethasone phosphate can be increased when it is combined with Norethynodrel.
Norgestrel The serum concentration of Betamethasone phosphate can be increased when it is combined with Norgestrel.
Cloprostenol The serum concentration of Betamethasone phosphate can be increased when it is combined with Cloprostenol.
Gestrinone The serum concentration of Betamethasone phosphate can be increased when it is combined with Gestrinone.

Target Protein

Glucocorticoid receptor NR3C1
Annexin A1 ANXA1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 22154197
    Salem II, Najib NM: Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects. Clin Ther. 2012 Jan;34(1):214-20. doi: 10.1016/j.clinthera.2011.11.022. Epub 2011 Dec 9.
  • PMID: 30285357
    Yasir M, Sonthalia S: Corticosteroid Adverse Effects .
  • PMID: 23300763
    Gardill BR, Vogl MR, Lin HY, Hammond GL, Muller YA: Corticosteroid-binding globulin: structure-function implications from species differences. PLoS One. 2012;7(12):e52759. doi: 10.1371/journal.pone.0052759. Epub 2012 Dec 26.
  • PMID: 15634032
    Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul